Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review.
Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review.
复制标题
DOI：
10.2147/ndt.s58096
复制
发表时间：
2014
影响因子：
3.2
通讯作者：
Treuer T
中科院分区：
文献类型：
--
作者：
Xue HB;Liu L;Zhang H;Montgomery W;Treuer T
尽管中国人口中有精神分裂症和双相情感障碍的负担，但缺乏针对特定国家的数据来指导从业者进行抗精神病治疗。这项系统性综述的主要目的是检查奥氮平在中国人群中的有效性、有效性和安全性的证据。使用涵盖国际和中国核心期刊的数据库进行系统的文献检索，检索词涉及精神分裂症和双相情感障碍、特定国家(中国、香港、台湾)和奥氮平治疗。在初步筛选之后，将纳入和排除标准应用于搜索结果，以确定从中提取数据的相关研究。总共检索了489篇出版物，确定了61项研究纳入其中。大多数研究与精神分裂症有关(n=54)，其中6项研究与双相情感障碍有关，1项研究与两种疾病都有关。国际期刊的研究方法和报道质量明显好于中文期刊。大多数研究包括相对较小的患者群体，持续时间较短。奥氮平在中国人群中的疗效得到了多项比较和非比较研究的证实，这些研究发现，在针对≥6周(精神分裂症)或≥3周(双相情感障碍)进行的研究中，症状指标在统计上显著减少。与有效性(停止治疗、生活质量和神经认知改善)相关的研究结果与在非中国人群中观察到的结果大体一致。奥氮平没有针对中国人群发出新的安全信号。接受奥氮平治疗的精神分裂症或双相情感障碍的中国人和非中国人表现出大致相似的反应。这些人群之间的差异，特别是在奥氮平与其他抗精神病药物的相对疗效方面，可能需要通过纳入这两个人群的研究来进一步研究。应鼓励使用当地数据为实践指南提供证据，并可能促进研究和研究报告质量的持续改进。
Despite the burden of schizophrenia and bipolar disorder in the Chinese population, country-specific data to guide practitioners regarding antipsychotic therapy are lacking. The primary aim of this systematic review was to examine evidence of the efficacy, effectiveness, and safety of olanzapine in Chinese populations. A systematic literature search was conducted using databases covering international and Chinese core journals using search terms related to schizophrenia and bipolar disorder, specified countries (People’s Republic of China, Hong Kong, Taiwan), and olanzapine treatment. Following initial screening, inclusion and exclusion criteria were applied to the search results to identify relevant studies from which data were extracted. A total of 489 publications were retrieved and 61 studies were identified for inclusion. Most studies were related to schizophrenia (n=54), with six studies related to bipolar disorder and one study related to both conditions. The quality of study methods and reporting in international journals was noticeably better than in Chinese language journals. Most studies included relatively small patient populations and were of short duration. The efficacy of olanzapine in Chinese populations was confirmed by multiple comparative and noncomparative studies that found statistically significant reductions in symptom measures in studies conducted for ≥6 weeks (schizophrenia) or ≥3 weeks (bipolar disorder). Findings related to effectiveness (treatment discontinuation, quality of life, and neurocognitive improvements) were generally consistent with those observed in non-Chinese populations. No new safety signals specific for Chinese populations were raised for olanzapine. Chinese and non-Chinese populations with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses. Differences between these populations, especially in relation to the relative efficacy of olanzapine versus other antipsychotics, may warrant further investigation via studies incorporating both populations. Use of local data to provide evidence for practice guidelines should be encouraged, and may promote ongoing improvements in the quality of research and study reporting.